The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention
Abstract
AIMS: Among patients with ST-elevation myocardial infarction (STEMI), reperfusion injury contributes to additional myocardial damage. MTP-131 is a cell-permeable peptide that preserves the integrity of cardiolipin, enhances mitochondrial energetics, and improves myocyte survival during reperfusion. METHODS AND RESULTS: EMBRACE STEMI is a multicentre, randomized, double-blind Phase 2a trial that evaluated the efficacy and safety of MTP-131 vs. placebo infused at a rate of 0.05 mg/kg/h for 1 h among first-time anterior STEMI subjects undergoing primary percutaneous coronary intervention (PCI) for a proximal or mid left anterior descending (LAD) artery occlusion. Administration of MTP-131 was not associated with a significant reduction in the primary endpoint, infarct size by creatine kinase-myocardial band (CK-MB) area under the curve (AUC) over 72 h (5785 ± 426 ng h/mL in placebo vs. 5570 ± 486 ng h/mL in MTP-131; ITALIC! P = NS). MTP-131 was not associated with an improvement in pre-specified magnetic resonance imaging, angiographic, electrocardiographic, or clinical outcomes. CONCLUSION: Among subjects with first-time anterior STEMI due to a proximal or mid LAD lesion who undergo successful PCI, administration of MTP-131 was safe and well tolerated. Treatment with MTP-131 was not associated with a decrease in myocardial infarct size as assessed by AUC0-72 of CK-MB.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phase I clinical trials established that the molecule was safe and well tolerated (360).”
From Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation (2019) · cites this paper as [360]
Citations
Cites
Yellon, D. M., & Hausenloy, D. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071667 · Cited by 3,797
Myocardial reperfusion: a double-edged sword?
D, E. B. M., & Kloner, R. A. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112160 · Cited by 1,368
Self-citationEffect of Cyclosporine on Reperfusion Injury in Acute Myocardial Infarction
Piot, C. A., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., Belghiti, R. E., Cung, T. T., Bonnefoy‐Cudraz, E., Angoulvant, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071142 · Cited by 1,339
Halestrap, A. P. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00533-9 · Cited by 1,244
Zhao, K., Zhao, G.-M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402999200 · Cited by 782
Ross, A. M., Gibbons, R. J., Stone, G. W., Kloner, R. A., & Alexander, R. W. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.061 · Cited by 608
Self-citationSzeto, H. H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12461 · Cited by 561
Stone, G. W. (2012) · JAMA · doi:10.1001/jama.2012.421 · Cited by 542
The APEX AMI Investigators (2007) · JAMA · doi:10.1001/jama.297.1.43 · Cited by 447
Ibáñez, B., Macaya, C., Sánchez-Brunete, V., Pizarro, G., Fernández‐Friera, L., Rodríguez, A. A. M., Fernández‐Ortíz, A., García-Ruiz, J. M., García‐Álvarez, A., Íñiguez, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003653 · Cited by 395
Cited by
Sorted by citations
Items 101–162 of 162
Nanoparticle Delivery of Mitoprotective Agents to Target Ischemic Heart Disease
Ong, S., Lu, S., Katwadi, K., Ismail, N. I., Kwek, X.-Y., & Hausenloy, D. J. (2017) · Future Cardiology · doi:10.2217/fca-2017-0012 · Cited by 17
Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model
Zhang, X., Zhang, Y., Zhang, M., Nakagawa, Y., Caballo, C. B., Szeto, H. H., Deng, X., & Rodeo, S. A. (2022) · The American Journal of Sports Medicine · doi:10.1177/03635465221107943 · Cited by 18
Campo, G. C., Pavasini, R., Morciano, G., Lincoff, M. A., Gibson, C. M., Kitakaze, M., Lønborg, J., Ahluwalia, A., Ishii, H., Frenneaux, M. P., et al. (2017) · Data in Brief · doi:10.1016/j.dib.2017.07.033 · Cited by 15
Self-citationParker, A. M., Lees, J. G., Murray, A. J., Velagic, A., Lim, S. Y., Blasio, M. J. D., & Ritchie, R. H. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101345 · Cited by 17
Schäfer, A., Akin, M., Diekmann, J., & König, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061509 · Cited by 16
Hortmann, M., Robinson, S., Mohr, M., Haenel, D., Mauler, M., Stallmann, D., Reinoehl, J., Duerschmied, D., Peter, K., Bode, C., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.088 · Cited by 14
Self-citationAlotaibi, K., Arulkumaran, N., Dyson, A., & Singer, M. (2025) · Clinical Science · doi:10.1042/cs20242074 · Cited by 14
Novel Findings and Therapeutic Targets on Cardioprotection of Ischemia/ Reperfusion Injury in STEMI
Li, J., Sun, D., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191105103417 · Cited by 13
Multicellular 3D models to study myocardial ischemia–reperfusion injury
Peletier, M. C., Zhang, X., Klein, S., & Kroon, J. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1494911 · Cited by 13
Johnson, T. W., Holt, J., Kleyman, A., Zhou, S., Sammut, E., Bruno, V., Gaupp, C., Stanzani, G., Martin, J., Arina, P., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103167 · Cited by 12
Mitochondrial ROS production during ischemia-reperfusion injury
Prag, H. A., Kula‐Alwar, D., Beach, T. E., Gruszczyk, A. V., Burger, N., & Murphy, M. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818606-0.00026-2 · Cited by 12
Wang, X., Guo, R., Guo, Y., Guo, Q., Yan, Y., Gong, W., Zheng, W., Wang, H., Xu, L., Ai, H., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.02.005 · Cited by 10
Daaboul, Y., Korjian, S., Weaver, W. D., Kloner, R. A., Giugliano, R. P., Carr, J., Neal, B. J., Chi, G., Cochet, M., Goodell, L., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.025 · Cited by 10
Self-citationInvestigational drugs in phase II clinical trials for acute coronary syndromes
Rout, A., Sukhi, A., Chaudhary, R., Bliden, K. P., Tantry, U. S., & Gurbel, P. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708324 · Cited by 11
Mitochondrial Targeted Interventions for AgingPreprint
Liu, S. Z., Chiao, Y. A., Rabinovitch, P. S., & Marcinek, D. J. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041199 · Cited by 11
Cellular and molecular approaches to enhance myocardial recovery after myocardial infarction
Parviz, Y., Waleed, M., Vijayan, S., Adlam, D., Lavi, S., Nooryani, A. A. A., Iqbal, J., & Stone, G. W. (2018) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2018.05.021 · Cited by 9
Mitochondrial Protective Agents for Ischemia/Reperfusion Injury
Kloner, R. A. (2017) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.005805 · Cited by 9
Self-citationTonet, E., Bernucci, D., Morciano, G., & Campo, G. C. (2018) · Advances in Interventional Cardiology · doi:10.5114/aic.2018.74349 · Cited by 8
Lu, Q., Yao, X., Zheng, H., Ou, J., You, J., Zhang, Q., Guo, W., Xu, J., Li, G., Liu, Q., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38584 · Cited by 8
Targeting respiratory virus-induced reactive oxygen species in airways diseases
Adams, T. J., Schuliga, M. J., Pearce, N., Bartlett, N. W., & Liang, M. (2025) · European Respiratory Review · doi:10.1183/16000617.0169-2024 · Cited by 9
Wang, W., Tai, S., Tao, J., Yang, L., Cheng, X., & Zhou, J. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101295 · Cited by 10
Qi, Y., Hu, M., Wang, Z., & Shang, W. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115725 · Cited by 7
Selecting heart failure patients for metabolic interventions
Booij, H. G., Koning, A. M., van Goor, H., de Boer, R. A., & Westenbrink, B. D. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1266939 · Cited by 7
Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach
Fabris, E., Selvarajah, A., Tavenier, A. H., Hermanides, R. S., Kedhi, E., Sinagra, G., & Hof, A. W. J. V. ’. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00531-y · Cited by 6
Targeting Mitochondrial Function in Heart Failure
Khan, M. S., & Butler, J. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.03.003 · Cited by 6
Dong, L., Zhou, Y., Wang, L., Mao, X., Wang, J., Du, Z., Che, X., & Li, Y. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70043 · Cited by 5
Lüscher, T. F. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw142 · Cited by 5
Lüscher, T. F. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx631 · Cited by 5
ST-segment elevation myocardial infarction: the new ESC Guidelines
Lüscher, T. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx792 · Cited by 5
Pedriali, G., Leo, S., Tiezzi, M., Colarusso, E. N., Morciano, G., Tremoli, E., & Pinton, P. (2026) · Basic Research in Cardiology · doi:10.1007/s00395-026-01162-z · Cited by 5
Acute Coronary Syndrome and Rheumatic Disease
Hill, A. P., Iqbal, S. B., Case, B. C., Shankar, A. A., & Merdler, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051490 · Cited by 5
Ji, X., Khdour, O. M., & Hecht, S. M. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0481 · Cited by 3
Development and Characterization of Innovative Multidrug Nanoformulation for Cardiac Therapy
Gendron, A., Domenichini, S., Zanna, S., Gobeaux, F., Piesse, C., Desmaële, D., & Varna, M. (2023) · Materials · doi:10.3390/ma16051812 · Cited by 3
Mitochondria for Cardiovascular Therapy: A Deep Dive into Drug Targets and Therapeutic Approaches
Semenzato, M., & Naón, D. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00405-2 · Cited by 3
Jędrzejewska, A., Braczko, A., Kawecka, A., Hellmann, M., Siondalski, P., Slominska, E. M., Kutryb-Zając, B. A., Yacoub, M. H., & Smolenski, R. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179886 · Cited by 3
Mitochondrial Quality Control in Macrophages During Cardiovascular Disease
Falconer, R., & Day, E. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.02.034 · Cited by 2
Lüscher, T. F. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx085 · Cited by 2
Marinović, J., Mihanovic, I., Maltar‐Strmečki, N., Bulat, C., Zanchi, J., & Ljubković, M. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.09.005 · Cited by 2
A multiple targeting rapamycin and SS31 conjugate enhances ischemic stroke therapy
Sun, A., Huang, W., Jin, K., Zhong, M., Yu, B., Li, X., Wang, Y., & Liu, H. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2440094 · Cited by 2
Kingma, J. G. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92838 · Cited by 2
Wang, Y., Wang, Z., Peng, Z., Feng, L., Tian, W., Zhang, S., Cao, L., Li, J., Liang, Y., Xu, Y., et al. (2024) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13904 · Cited by 2
Role of Oxidative Stress in Myocardial Ischemia and Infarction
Jugdutt, B. I., & Jugdutt, B. A. (2019) · Springer eBooks · doi:10.1007/978-981-13-8273-4_14 · Cited by 2
Li, G., Li, T., Deng, Y., Deng, X., Chen, C., Yu, B., & Zhang, K. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.08.002 · Cited by 1
Tan, D., Lye, Y. E., Patel, P., Minn, N. A., Le, A. C., Bobik, A., & Kyaw, T. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104409 · Cited by 1
Nasoufidou, A., Bantidos, M. G., Kofos, C., Stalikas, N., Mitsis, A., Stachteas, P., Karakasis, P., Fasoula, M., Fyntanidou, B., Kassimis, G., et al. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2703072 · Cited by 2
Seto, A. H., Safirstein, J. G., Anwaruddin, S., Dehghani, P., Shah, B., & Tremmel, J. A. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26474 · Cited by 1
Shi, J., Dai, W., Carreño, J. E., Hale, S. L., Kloner, R. A., & Kay, G. L. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.026 · Cited by 1
Self-citationPrevention of Microvascular Obstruction by Addressing Ischemia Reperfusion Injury—Part B
Pizarro, G., Fernández‐Jiménez, R., & Ibáñez, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812528-1.00016-6
Cardiac Remodeling: The Course Towards Heart Failure-II. Diagnostic and Therapeutic Approaches
Cokkinos, D. V. (2019) · Springer eBooks · doi:10.1007/978-3-319-98186-4_13
Substrate Remodeling in Heart Failure
Iakovou, A., Guymer, S., & Chowdhury, R. A. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-24219-0_13
Omoto, A. C. M. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-21022020-155407
Khare, V., Gupta, S., Bisht, P., & Garabadu, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00013-7
Environmental and genetic influence of circadian rhythm over cardiac metabolism and disease
Orlowska, M. K. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.246041
Effect of Shenfu Injection on Myocardial Injury After Primary PCI for STEMI: The RESTORE TrialPreprint
Wang, X., Fan, Z., Jiang, J., Guo, J., Wang, Z., Ma, L., He, R., Su, G., Liu, H., Yin, D., et al. (2024) · medRxiv · doi:10.1101/2024.07.01.24309807
Reviving the Mitochondria: A Hopeful Horizon in Refractory Heart Failure
Ahmed, Z., Rehman, F. A., & Bokhari, S. F. H. (2025) · Cureus · doi:10.7759/cureus.91710
Development of new nanoformulations for cardiac therapy
Gendron, A. (2023) · theses.fr (ABES) · doi:10.70675/9971639dz2d7fz4d8fza1c1z711c3637b124
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence
Xie, L., Wu, J., Fan, J., Krager, K. J., Aykin‐Burns, N., Li, S., Børsheim, E., Qi, X., Boerma, M., & Zhang, H. (2026) · Journal of Radiation Research · doi:10.1093/jrr/rrag048
Xue, X., 廖系晗, Ji, X., Huang, K., Wu, H., & Li, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1852905
Awasthi, V., Dasari, T. W., & Tanaka, K. A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00552
Cancer Outcomes in Cardiovascular Trials of Inflammation-Targeting Therapeutics
Yousif, L. I. E., Meijers, W. C., & de Boer, R. A. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2026.07.011
Cardiovascular–kidney–metabolic syndrome as a mitochondrial systems disorder
Shen, L., Abel, E. D., Arany, Z. P., Baur, J. A., Pei, L., & Suszták, K. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01127-4
Metadata
- Authors
- Gibson, C. M., Giugliano, R. P., Kloner, R. A., Bode, C., Tendera, M., Jánosi, A., Merkely, B., Godlewski, J., Halaby, R., Korjian, S., Daaboul, Y., Chakrabarti, A. K., Spielman, K., Neal, B. J., & Weaver, W. D.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Brigham and Women's Hospital (US)
- University of Southern California (US)
- University of Freiburg (DE)
- Gottsegen National Cardiovascular Center (HU)
- John Paul II Hospital (PL)
- Harvard University (US)
- Eastern Virginia Medical School (US)
- Henry Ford Hospital (US)
- Corresponding author
- Gibson, C. Michael
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-19
- Volume
- 37
- Issue
- 16
- Pages
- 1296.1-1303
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2176701303
- Cited by
- 162
- References
- 36
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 15 · 2023: 12 · 2022: 19 · 2021: 9 · 2020: 19 · 2019: 13 · 2018: 17 · 2017: 19 · 2016: 18
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ST-elevation myocardial infarction, ischemia-reperfusion injury, primary percutaneous coronary intervention, cell-permeable peptide, cardiolipin, mitochondrial bioenergetics, myocardial infarct size, CK-MB, left anterior descending artery occlusion, drug safety and tolerability
- MeSH terms
- ST Elevation Myocardial Infarction, Double-Blind Method, Humans, Oligopeptides, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
